PARP Inhibition Restores Extrinsic Apoptotic Sensitivity in Glioblastoma

Phase II Trial of Mapatumumab, a Fully Human Agonist Monoclonal Antibody to Tumor Necrosis Factor-Related Apoptosis-Inducing Ligand Receptor 1 (TRAIL-R1), in Combination With Paclitaxel and Carboplatin in Patients With Advanced Non–Small-Cell Lung Cancer

(2014) Joachim von Pawel et al.   Clinical Lung Cancer

Role of Activating Transcription Factor 3 (ATF3) in Endoplasmic Reticulum (ER) Stress-induced Sensitization of p53-deficient Human Colon Cancer Cells to Tumor Necrosis Factor (TNF)-related Apoptosis-inducing Ligand (TRAIL)-mediated Apoptosis through Up-regulation of Death Receptor 5 (DR5) by Zerumbone and Celecoxib

(2014) Makoto Edagawa et al.   JOURNAL OF BIOLOGICAL CHEMISTRY

Effect of miR-142-3p on the M2 Macrophage and Therapeutic Efficacy Against Murine Glioblastoma

(2014) Shuo Xu et al.   JNCI-Journal of the National Cancer Institute

PI3K and Bcl-2 Inhibition Primes Glioblastoma Cells to Apoptosis through Downregulation of Mcl-1 and Phospho-BAD

(2014) Fresia Pareja et al.   MOLECULAR CANCER RESEARCH

Interferon-  Induces Loss of Spherogenicity and Overcomes Therapy Resistance of Glioblastoma Stem Cells

(2014) C. Happold et al.   MOLECULAR CANCER THERAPEUTICS

Bcl2L13 is a ceramide synthase inhibitor in glioblastoma

(2014) S. A. Jensen et al.   PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA

Single-cell RNA-seq highlights intratumoral heterogeneity in primary glioblastoma

(2014) A. P. Patel et al.   SCIENCE

PARP-1 Regulates Resistance of Pancreatic Cancer to TRAIL Therapy

(2013) K. Yuan et al.   CLINICAL CANCER RESEARCH

Poly(adenosine diphosphate-ribose) polymerase expression in BRCA-proficient ovarian high-grade serous carcinoma; association with patient survival

(2013) Alex Gan et al.   HUMAN PATHOLOGY

Novel Insights into the Synergistic Interaction of a Thioredoxin Reductase Inhibitor and TRAIL: The Activation of the ASK1-ERK-Sp1 Pathway

(2013) Tingting Lin et al.   PLoS One

Dual Inactivation of Akt and ERK by TIC10 Signals Foxo3a Nuclear Translocation, TRAIL Gene Induction, and Potent Antitumor Effects

(2013) J. E. Allen et al.   Science Translational Medicine

TRAIL on trial: preclinical advances in cancer therapy

(2013) Daniel W. Stuckey et al.   TRENDS IN MOLECULAR MEDICINE

Identification of DR5 as a critical, NF-κB-regulated mediator of Smac-induced apoptosis

(2013) I Eckhardt et al.   Cell Death & Disease

Utilization of the cellular stress response to sensitize cancer cells to TRAIL-mediated apoptosis

(2012) Markus David Siegelin   EXPERT OPINION ON THERAPEUTIC TARGETS

Phase I Trial and Pharmacokinetic Study of Lexatumumab in Pediatric Patients With Solid Tumors

(2012) Melinda S. Merchant et al.   JOURNAL OF CLINICAL ONCOLOGY

Histone deacetylase inhibitors sensitize glioblastoma cells to TRAIL-induced apoptosis by c-myc-mediated downregulation of cFLIP

(2012) A Bangert et al.   ONCOGENE

Heterogeneity of primary glioblastoma cells in the expression of caspase-8 and the response to TRAIL-induced apoptosis

(2011) Ling Qi et al.   APOPTOSIS

Exploiting the mitochondrial unfolded protein response for cancer therapy in mice and human cells

(2011) Markus D. Siegelin et al.   JOURNAL OF CLINICAL INVESTIGATION

Cytoplasmic Poly(Adenosine Diphosphate–Ribose) Polymerase Expression Is Predictive and Prognostic in Patients With Breast Cancer Treated With Neoadjuvant Chemotherapy

(2011) Gunter von Minckwitz et al.   JOURNAL OF CLINICAL ONCOLOGY

Phase II trial of mapatumumab, a fully human agonistic monoclonal antibody that targets and activates the tumour necrosis factor apoptosis-inducing ligand receptor-1 (TRAIL-R1), in patients with refractory colorectal cancer

(2010) T Trarbach et al.   BRITISH JOURNAL OF CANCER

Clinically relevant doses of chemotherapy agents reversibly block formation of glioblastoma neurospheres

(2010) Alicia M. Mihaliak et al.   CANCER LETTERS

Synergistic Chemosensitivity of Triple-Negative Breast Cancer Cell Lines to Poly(ADP-Ribose) Polymerase Inhibition, Gemcitabine, and Cisplatin

(2010) K. Hastak et al.   CANCER RESEARCH

 -Secretase Inhibitors Enhance Temozolomide Treatment of Human Gliomas by Inhibiting Neurosphere Repopulation and Xenograft Recurrence

(2010) C. A. Gilbert et al.   CANCER RESEARCH

Differentiation Therapy Exerts Antitumor Effects on Stem-like Glioma Cells

(2010) B. Campos et al.   CLINICAL CANCER RESEARCH

A genome-wide RNA interference screen reveals an essential CREB3L2-ATF5-MCL1 survival pathway in malignant glioma with therapeutic implications

(2010) Zhi Sheng et al.   NATURE MEDICINE

Stem-cell-like glioma cells are resistant to TRAIL/Apo2L and exhibit down-regulation of caspase-8 by promoter methylation

(2009) David Capper et al.   ACTA NEUROPATHOLOGICA

Is TRAIL the holy grail of cancer therapy?

(2009) Thomas Newsom-Davis et al.   APOPTOSIS

In vitro and In vivo Radiosensitization of Glioblastoma Cells by the Poly (ADP-Ribose) Polymerase Inhibitor E7016

(2009) A. L. Russo et al.   CLINICAL CANCER RESEARCH

Epigenetic Silencing of Death Receptor 4 Mediates Tumor Necrosis Factor-Related Apoptosis-Inducing Ligand Resistance in Gliomas

(2009) A. Elias et al.   CLINICAL CANCER RESEARCH

ABT-737 Induces Expression of the Death Receptor 5 and Sensitizes Human Cancer Cells to TRAIL-induced Apoptosis

(2008) Jin H. Song et al.   JOURNAL OF BIOLOGICAL CHEMISTRY

CD95 Stimulation Results in the Formation of a Novel Death Effector Domain Protein-containing Complex

(2008) Inna N. Lavrik et al.   JOURNAL OF BIOLOGICAL CHEMISTRY

Quercetin promotes degradation of survivin and thereby enhances death-receptor–mediated apoptosis in glioma cells

(2008) Markus D. Siegelin et al.   NEURO-ONCOLOGY

Apoptosis-based treatment of glioblastomas with ABT-737, a novel small molecule inhibitor of Bcl-2 family proteins

(2008) K E Tagscherer et al.   ONCOGENE